Report cover image

Global Bevacizumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20356715

Description

Summary

According to APO Research, The global Bevacizumab Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Bevacizumab Injection include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Bevacizumab Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Bevacizumab Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Bevacizumab Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bevacizumab Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Bevacizumab Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Bevacizumab Injection sales, projected growth trends, production technology, application and end-user industry.

Bevacizumab Injection Segment by Company

Biocon
Cadila Pharmaceuticals
Centus
Dr Reddy's
Genentech
Hetero Group
Samsung Bioepis
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Mylan
Bevacizumab Injection Segment by Type

100mg
400mg
Bevacizumab Injection Segment by Application

Age-related macular degeneration (AMD)
Ovarian Cancer
Others
Bevacizumab Injection Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bevacizumab Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bevacizumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Bevacizumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Bevacizumab Injection Market Size, 2020 VS 2024 VS 2031
1.3 Global Bevacizumab Injection Market Size Estimates and Forecasts (2020-2031)
1.4 Global Bevacizumab Injection Sales Estimates and Forecasts (2020-2031)
1.5 Global Bevacizumab Injection Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Bevacizumab Injection Market Dynamics
2.1 Bevacizumab Injection Industry Trends
2.2 Bevacizumab Injection Industry Drivers
2.3 Bevacizumab Injection Industry Opportunities and Challenges
2.4 Bevacizumab Injection Industry Restraints
3 Bevacizumab Injection Market by Manufacturers
3.1 Global Bevacizumab Injection Revenue by Manufacturers (2020-2025)
3.2 Global Bevacizumab Injection Sales by Manufacturers (2020-2025)
3.3 Global Bevacizumab Injection Average Sales Price by Manufacturers (2020-2025)
3.4 Global Bevacizumab Injection Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Bevacizumab Injection Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Bevacizumab Injection Manufacturers, Product Type & Application
3.7 Global Bevacizumab Injection Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Bevacizumab Injection Market CR5 and HHI
3.8.2 Global Top 5 and 10 Bevacizumab Injection Players Market Share by Revenue in 2024
3.8.3 2024 Bevacizumab Injection Tier 1, Tier 2, and Tier 3
4 Bevacizumab Injection Market by Type
4.1 Bevacizumab Injection Type Introduction
4.1.1 100mg
4.1.2 400mg
4.2 Global Bevacizumab Injection Sales by Type
4.2.1 Global Bevacizumab Injection Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Bevacizumab Injection Sales by Type (2020-2031)
4.2.3 Global Bevacizumab Injection Sales Market Share by Type (2020-2031)
4.3 Global Bevacizumab Injection Revenue by Type
4.3.1 Global Bevacizumab Injection Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Bevacizumab Injection Revenue by Type (2020-2031)
4.3.3 Global Bevacizumab Injection Revenue Market Share by Type (2020-2031)
5 Bevacizumab Injection Market by Application
5.1 Bevacizumab Injection Application Introduction
5.1.1 Age-related macular degeneration (AMD)
5.1.2 Ovarian Cancer
5.1.3 Others
5.2 Global Bevacizumab Injection Sales by Application
5.2.1 Global Bevacizumab Injection Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Bevacizumab Injection Sales by Application (2020-2031)
5.2.3 Global Bevacizumab Injection Sales Market Share by Application (2020-2031)
5.3 Global Bevacizumab Injection Revenue by Application
5.3.1 Global Bevacizumab Injection Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Bevacizumab Injection Revenue by Application (2020-2031)
5.3.3 Global Bevacizumab Injection Revenue Market Share by Application (2020-2031)
6 Global Bevacizumab Injection Sales by Region
6.1 Global Bevacizumab Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Bevacizumab Injection Sales by Region (2020-2031)
6.2.1 Global Bevacizumab Injection Sales by Region (2020-2025)
6.2.2 Global Bevacizumab Injection Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Bevacizumab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Bevacizumab Injection Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Bevacizumab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Bevacizumab Injection Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Bevacizumab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Bevacizumab Injection Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Bevacizumab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Bevacizumab Injection Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Bevacizumab Injection Revenue by Region
7.1 Global Bevacizumab Injection Revenue by Region
7.1.1 Global Bevacizumab Injection Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Bevacizumab Injection Revenue by Region (2020-2025)
7.1.3 Global Bevacizumab Injection Revenue by Region (2026-2031)
7.1.4 Global Bevacizumab Injection Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Bevacizumab Injection Revenue (2020-2031)
7.2.2 North America Bevacizumab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Bevacizumab Injection Revenue (2020-2031)
7.3.2 Europe Bevacizumab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Bevacizumab Injection Revenue (2020-2031)
7.4.2 Asia-Pacific Bevacizumab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Bevacizumab Injection Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Bevacizumab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Biocon
8.1.1 Biocon Comapny Information
8.1.2 Biocon Business Overview
8.1.3 Biocon Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Biocon Bevacizumab Injection Product Portfolio
8.1.5 Biocon Recent Developments
8.2 Cadila Pharmaceuticals
8.2.1 Cadila Pharmaceuticals Comapny Information
8.2.2 Cadila Pharmaceuticals Business Overview
8.2.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
8.2.5 Cadila Pharmaceuticals Recent Developments
8.3 Centus
8.3.1 Centus Comapny Information
8.3.2 Centus Business Overview
8.3.3 Centus Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Centus Bevacizumab Injection Product Portfolio
8.3.5 Centus Recent Developments
8.4 Dr Reddy's
8.4.1 Dr Reddy's Comapny Information
8.4.2 Dr Reddy's Business Overview
8.4.3 Dr Reddy's Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Dr Reddy's Bevacizumab Injection Product Portfolio
8.4.5 Dr Reddy's Recent Developments
8.5 Genentech
8.5.1 Genentech Comapny Information
8.5.2 Genentech Business Overview
8.5.3 Genentech Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Genentech Bevacizumab Injection Product Portfolio
8.5.5 Genentech Recent Developments
8.6 Hetero Group
8.6.1 Hetero Group Comapny Information
8.6.2 Hetero Group Business Overview
8.6.3 Hetero Group Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Hetero Group Bevacizumab Injection Product Portfolio
8.6.5 Hetero Group Recent Developments
8.7 Samsung Bioepis
8.7.1 Samsung Bioepis Comapny Information
8.7.2 Samsung Bioepis Business Overview
8.7.3 Samsung Bioepis Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
8.7.5 Samsung Bioepis Recent Developments
8.8 Amgen
8.8.1 Amgen Comapny Information
8.8.2 Amgen Business Overview
8.8.3 Amgen Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Amgen Bevacizumab Injection Product Portfolio
8.8.5 Amgen Recent Developments
8.9 Bayer
8.9.1 Bayer Comapny Information
8.9.2 Bayer Business Overview
8.9.3 Bayer Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Bayer Bevacizumab Injection Product Portfolio
8.9.5 Bayer Recent Developments
8.10 Pfizer
8.10.1 Pfizer Comapny Information
8.10.2 Pfizer Business Overview
8.10.3 Pfizer Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Pfizer Bevacizumab Injection Product Portfolio
8.10.5 Pfizer Recent Developments
8.11 Eli Lilly
8.11.1 Eli Lilly Comapny Information
8.11.2 Eli Lilly Business Overview
8.11.3 Eli Lilly Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Eli Lilly Bevacizumab Injection Product Portfolio
8.11.5 Eli Lilly Recent Developments
8.12 Roche
8.12.1 Roche Comapny Information
8.12.2 Roche Business Overview
8.12.3 Roche Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Roche Bevacizumab Injection Product Portfolio
8.12.5 Roche Recent Developments
8.13 Mylan
8.13.1 Mylan Comapny Information
8.13.2 Mylan Business Overview
8.13.3 Mylan Bevacizumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Mylan Bevacizumab Injection Product Portfolio
8.13.5 Mylan Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Bevacizumab Injection Value Chain Analysis
9.1.1 Bevacizumab Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Bevacizumab Injection Production Mode & Process
9.2 Bevacizumab Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Bevacizumab Injection Distributors
9.2.3 Bevacizumab Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.